PMGC Holdings (ELAB) Non-Current Assets (2022 - 2026)
PMGC Holdings (ELAB) posted Non-Current Assets of $11262.0 for Q1 2026, down 99.46% sequentially from $2.1 million in Q4 2025, and down 99.46% YoY from $2.1 million in Q1 2025.
PMGC Holdings (ELAB) Non-Current Assets (2022 - 2026) Analysis & Trends
PMGC Holdings has reported Non-Current Assets for 5 years, with the latest figure at $11262.0 in Q1 2026.
- Quarterly Non-Current Assets fell 99.46% year-over-year to $11262.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11262.0 (down 99.88% YoY) and the FY2025 annual result came in at $2.1 million, up 192498.62% from the prior year.
- Non-Current Assets declined to $11262.0 in Q1 2026 per ELAB's latest filing, from $2.1 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $306.4 million in Q3 2023 and troughed at $1086.0 in Q4 2024.
- A 5-year average of $27.1 million and a median of $2.1 million in 2025 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2024 and 2025: Non-Current Assets sank 99.6% in 2024, then surged 192498.62% in 2025.
- Over 5 years, Non-Current Assets stood at $340861.0 in 2022, then declined by 20.65% to $270474.0 in 2023, then tumbled by 99.6% to $1086.0 in 2024, then soared by 192498.62% to $2.1 million in 2025, then tumbled by 99.46% to $11262.0 in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $11262.0, $2.1 million, and $5.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 938.60 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 468.65 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 18.06 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 6.80 Bn |
| 10 | PMGC Holdings | 3.01 Mn | -15.78 Mn | 385,691.00 | 15.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11,262.00 |
| Dec 31, 2025 | 2.09 Mn |
| Sep 30, 2025 | 5.17 Mn |
| Jun 30, 2025 | 2.07 Mn |
| Mar 31, 2025 | 2.07 Mn |
| Dec 31, 2024 | 1,086.00 |
| Sep 30, 2024 | 2.98 Mn |
| Jun 30, 2024 | 3.05 Mn |
| Mar 31, 2024 | 1.09 Mn |
| Dec 31, 2023 | 270,474.00 |
| Sep 30, 2023 | 306.39 Mn |
| Dec 31, 2022 | 340,861.00 |